Floatz logo

rc48-adc

Bevacizumab

Sun Yat-sen Universityantibody_drug_conjugateActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

10 Active assets in the Bevacizumab cohort.

Asset / SponsorPhaseRating
Iparomlimab
Nanfang Hospital, Southern Medical University
Phase 4BB
Calcium folinate pentahydrate
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2B
Irinotecan
Nanfang Hospital, Southern Medical University
Phase 2B
(+)-VINCRISTINE
Nanfang Hospital, Southern Medical University
Phase 2B
FLUOROURACILUM
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2CCC

View all 10 →

Same molecule, other indications

rc48-adc is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →